Neurology

Fingolimod (Gilenya), which is approved by the FDA to treat multiple sclerosis flare-ups, may also block HIV and reduce the latent reservoir.

Pharmaceutical treatments have been at a standstill, but promising drugs are on the horizon.

Ozanimod (Zeposia) became the third oral S1P modulator approved by the FDA for the treatment of multiple sclerosis,

A new blood test for Alzheimer disease could provide a more sensitive, accurate indicator of plaques and tangles corresponding to the disease in living people.

Risdiplam is the first at-home, orally administered treatment for spinal muscular atrophy in adults and children aged 2 months and older.

Research may address the lack of effective treatments for mental fatigue among patients with multiple sclerosis.

Spinal muscular atrophy is the leading genetic cause of death in infants.

The combination medication is used to treat the symptoms of tension or muscle contraction headaches. The drug is only available via a prescription from a physician.

New molecules could the brain’s immune system to better control epilepsy.

Tofersen proves safe in clinical trials in the treatment of amyotrophic lateral sclerosis.

The study concluded that pharmacists reportedly scored higher on the knowledge test than neurologists and nurse practitioners.

Regardless of the channel through which a specialty medication is billed and filled, management strategies will be an essential cornerstone to controlling costs.

Low back pain is one of the leading reasons people seek medical care and the number 1 cause of disability globally.

The key to better outcomes for patients with MS is to address it early.

According to a recent study published in Gut, inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn disease, is associated with a more than doubled likelihood of developing dementia.

Dravet syndrome is a life-threatening, rare, and chronic form of epilepsy and is often characterized by severe, unrelenting seizures despite medical treatment, according to the FDA press release.

Cognitive impairment is extremely common among patients with MS, affecting approximately two-thirds of this patient population.

The NIA is currently funding more than 230 active clinical trials on AD and related dementias. Of those, more than 100 are nondrug interventions, such as exercise, diet, cognitive training, sleep, or combination therapies.

After up to 4.8 years of treatment with nusinersen, 100% of children with spinal muscular atrophy (SMA) who were treated pre-symptomatically are still alive.

The researchers identified 87 articles using the PubMed and PsycINFO databases and the 2017 American Academy of Neurology (AAN) criteria for therapeutic trials.

The authors posited that teriflunomide could prevent an excessive immune response while still maintaining enough defense against the virus.

SE requires prompt intervention to terminate seizure activity to prevent neuronal damage and complications.

Galcanezumab-gnlm (Emgality, Lilly) has received FDA-approval for the preventive treatment of migraine in adults and for the treatment of episodic cluster headache in adults.

As Alzheimer disease research evolves beyond targeting a single pathology, interventions should coordinate disease stage with pathology and the patient’s presenting characteristics.

According to a recent study, people with a higher risk of cardiovascular disease demonstrate an increase in cognitive decline, including a rise in the typical markers of Alzheimer disease.